Don't forget the turnover/sales for EPPuse after EMA approval. In Europa there are apr. 3.500 EPP patients.
3.500 x apr. € 30.000 = 105 mln.
If only half of the patients are going to use Scenesse Clinuvel will be a profitable biotechcompany.
nomura "maa review should complete by start 4q, page-8
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$9.99 |
Change
-0.130(1.28%) |
Mkt cap ! $500.7M | |||
| Open | High | Low | Value | Volume |
| $10.08 | $10.30 | $9.93 | $695.9K | 69.11K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 9911 | $9.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.01 | 344 | 1 |
View Market Depth
| Last trade - 16.10pm 02/07/2025 (20 minute delay) ? |
| CUV (ASX) Chart |